Last reviewed · How we verify
Mer Detox 6019 (mer)
Mer Detox 6019, marketed by Pfizer, is positioned in the niche market addressing exhaustion or weakness. A key strength lies in its unique mechanism of action, which remains unspecified, setting it apart from competitors. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | mer |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Exhaustion or Weakness
- Muscle Soreness
- Minor Joint Pain or Stiffness
- Headache
- Dizziness
- Dry, Itchy, or Cracked Skin
- Constipation
- Diarrhea
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Clopidogrel
- Ibuprofen
- Naproxen
- Celecoxib
- Pentoxifylline
- Dipyridamole
- Ticlopidine
- Cilostazol
- Dabigatran
- Rivaroxaban
Key clinical trials
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (PHASE3)
- Phase 2 Study of WGI-0301 for Advanced HCC (PHASE2)
- Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism
- Injury Incidence, Severity and Burden in Elite Youth Rugby Players
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1, PHASE2)
- Evaluation of a Collaborative Mental Health Care System (NA)
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors (PHASE1, PHASE2)
- A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mer Detox 6019 CI brief — competitive landscape report
- Mer Detox 6019 updates RSS · CI watch RSS
- Pfizer portfolio CI